Leukocyte involvement in the signs and symptoms of chronic venous disease. Perspectives for therapy

Clinical Hemorheology and Microcirculation

Volumn 37, Issue 3, 2007, Pages 277-290

  Boisseau, Michel René ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Chronic venous disease; Cramp; Edema; Heaviness; Leg; Leukocytes; Mast cell

Indexed keywords

ALLOPURINOL; BRADYKININ; DAFLON; ELASTASE; FREE RADICAL; GELATINASE B; ILOPROST; INTEGRIN; L SELECTIN; LACTOFERRIN;

CELL ADHESION; CELL CYCLE; CHEMORECEPTOR; EDEMA; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOXIA; LEUKOCYTE; MAST CELL; NEUTROPENIA; NEUTROPHIL; REVIEW; SHEAR STRESS; VARICOSIS; VEIN DISEASE; VEIN PAIN; VEIN WALL; VISCERAL PAIN;

EID: 35648957615     PISSN: 13860291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. A. Bradbury, C. Evans, P. Allan, A. Lee, V. Ruckley and F.G. Fowkes, What are the symptoms of varicose veins? Edinburgh vein study cross sectional population survey, BMJ 318 (1999), 353-356.
2. M.R. Boisseau, Peut-on proposer une stratégie d'indication des veinotoniques? Plaidoyer en vue d'un consensus. Position des médications veno-actives vis-à-vis de la douleur au cours de la maladie veineuse chronique, Phlebologie 58 (2005), 77-81.
3. E. Tison, A. Crochard, D. Léger, S. Bouee, E. Lainey and A. El Hasnaoui, Epidemiology of restless legs syndrome in French adults: a nationwide survey: The INSTANT Study, Neurology 65 (2005), 239-246.
4. B. Eklof, R.B. Rutherford, J.J. Bergan et al., Revision of the CEAP classification for chronic venous disorders: consensus statement, For the American Venous Forum International Ad Hoc Committee for Revision of the CEAP Classification, J. Vasc. Surg. 40 (2004), 1248-1252.
5. A. Bradbury, C.J. Evans, P. Allan, A.J. Lee and V. Ruckley, The relationship between lower limb symptoms and superficial and deep venous reflux on duplex ultrasonography, J. Vasc. Surg. 32 (2000), 921-931.
6. M.N. Isaacs, Symptomatology of vein diseases, Dermatol. Surg. 21 (1995), 321-323.
7. R.D. Langer, E. Ho, J.O. Denenberg, A. Fronek, M. Allison and M.H. Criqui, Relationship between symptoms and venous disease. The San Diego population study, Arch. Int. Med. 165 (2005), 1420-1424.
8. K. Kroger, C. Ose, G. Rudofsky, J. Roesener and H. Hirche, Symptoms in individuals with small cutaneous veins, Vasc. Med. 7 (2002), 13-17.
9. M.H. Howlader and P.D. Coleridge-Smith, Symptoms of chronic venous disease and association with systemic inflammatory markers, J. Vasc. Surg. 38 (2003), 950-954.
10. G. Jantet, Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids, Angiology 53 (2002), 245-256.
11. J. Edwards, G.M. McMullin, H. Ardoe, M. Saharay, H.J. Scott and L. Wilkinson, White blood cell distribution in chronic venous insufficiency, in: Microcirculation in Venous Disease, P.D. Coleridge-Smith, ed., Landers Bioscience, Austin, TX (1998), pp. 117-140.
12. A. Atherton and G.V.R. Born, Relationship between the velocity of rolling granulocytes and that of the blood flow in venules, J. Physiol. 233 (1973), 157-165.
13. S. Takase, G. Schmid-Shönbein and J.J. Bergan, Leukocyte activation in patients with venous insufficiency, J. Vasc. Surg. 30 (1999), 148-156.
14. S. Takase, J.J. Bergan and G.W. Schmid-Shönbein, Expression of adhesive molecules and cytokines on saphenous veins in chronic venous insufficiency, Ann. Vasc. Surg. 14 (2000), 427-435.
15. M. Takahashi, U. Ikeda and J.I. Masuyama et al., Monocyte-endothelial cell interaction induces expression of adhesion molecules on human umbilical cord endothelial cells, Cardiovasc. Res. 32 (1996), 422-429.
16. K. Ley, M. Allieta, D.C. Bullard and S. Morgan, Importance of E-selectin for firm adhesion in vivo, Circ. Res. 83 (1998), 287-294.
17. C. Moyses, S.A. Cederholm-Williams and C.C. Michel, Haemoconcentration and accumulation of white cells in the feet during venous stasis, Int. J. Microcirc. Clin. Exp. 5 (1987), 311-320.
18. P.R. Thomas, G.B. Nash and J.A. Dormandy, White cell accumulation in dependent legs of patients with venous hypertension: a possible mechanism for trophic changes in the skin, Br. Med. J. 296 (1988), 1693-1695.
19. R.J. Whiston, M.B. Hallett, E.V. Davies, K.G. Harding and I.F. Lane, Inappropriate neutrophil activation in venous disease, Br. J. Surg. 81 (1994), 695-698.
20. J.J. Bergan, G. Schmid-Schônbein, P. Coleridge-Smith, A. Nicolaides, M. Boisseau and B. Eklof, Chronic venous disease, N. Engl. J. Med. 355 (2006), 488-498.
21. M. Saharay, D.A. Shields, S.N. Georgiannos, J.B. Porter, J.H. Scurr and P.D. Coleridge-Smith, Endothelial activation in patients with chronic venous disease, Eur. J. Vasc. Endovasc. Surg. 15 (1998), 342-349.
22. M. Peschen, T. Lahaye, B. Hennig, A. Weyl, J.C. Simon and W. Vanscheidt, Expression of the adhesion molecules ICAM-1, VCAM-1, LFA-1 and VLA-4 in the skin is modulated in progressing stages of chronic venous insufficiency, Acta Derm. Venereol. 79 (1999), 27-32.
23. P.J. Pappas, F.R. Fallek and A. Garcia et al., Role of leukocyte activation in patients with venous stasis ulcers, J. Surg. Res. 59 (1995), 553-559.
24. M.P. Jacob, M. Cazaubon and A. Scemama et al., Plasma matrix metalloproteinase-9 as a marker of blood stasis in varicose veins, Circulation. 106 (2002), 535-538.
25. D. Shields and M. Saharay, White cell activation, in: Microcirculation in Venous Disease, 2nd edition, P.D. Coleridge-Smith, ed., Landers Bioscience, Austin, TX (1998), pp. 140-174.
26. C. Michiels, T. Arnould and J. Remacle, Endothelial cell responses to hypoxia: initiation of a cascade of cellular interactions, Biochem. Biophys. Acta 1497 (2000), 1-10.
27. M. Boisseau, Effect of shear stress in vascular endothelial changes, Phlebolymphology 40 (2003), 143-155.
28. T. Yamada, S. Tomita, M. Mori, E. Sasatomi, E. Suenaga and T. Itoh, Increased mast cell infiltration in varicose vein of the lower limbs: a possible role in the development of varices, Surgery 119 (1996), 494-497.
29. G.L. Sayer and P.D. Smith, Immunocytochemical characterisation of the inflammatory cell infiltrate of varicose veins, Eur. J. Vasc. Endovasc. Surg. 28 (2004), 479-483.
30. T. Ono, J.J. Bergan, G.W. Schmid-Shönbein and S. Takase, Monocyte infiltration into venous valves, J. Vasc. Surg. 27 (1998), 158-166.
31. D. Nolte, S. Pickelmann and M. Mollmann et al., Effects of the phlebotonic drug Daflon 500 mg on postischemic microvascular disturbances in striated skin muscle: an intravital microscopic study in the hamster, J. Lab. Clin. Med. 134 (199), 526-535.
32. J.W. Breslin, P.J. Pappas, J.J. Cerveira, R.W. Hobson 2nd and W.N. Duran, VEGF increases endothelial permeability by separate signalling pathways ERK-1/2 and nitric oxide, Am. J. Physiol. Heart Circ. Physiol. 284 (2003), H92-H100.
33. J. Zilberberg and N.R. Harris, Synergism between leukocyte adherence and shear determines venular permeability in the presence of nitric oxide, Microvasc. Res. 62 (2001), 410-420.
34. S. Nees, G. Juchem, R. Fink and H. Abbogast, Influence of polymorphonuclear leucocytes and platelets on the barrier function of cultured venular endothelial cells, in: Sixth World Congress for Microcirculation, K. Messmer and W.M. Kübler, eds, Monduzzi Editore, Bologna, Italy (1996), 401-404.
35. D. Le Bars and J.C. Willer, Physiologie de la douleur, EMI-INSERM 0331/0349, Paris, France (2005).
36. N. Danziger, [Physiology of pain in venous disease], Concours Med. 126 (2004), 1521-1525.
37. D. Kindgen-Milles, Effects of prostaglandin E1 on the intensity of bradykinin-evoked pain from skin and veins in humans. Eur. J. Pharmacol. 294 (1995), 491-496.
38. P.D. Drummond, The effect of cutaneous mast-cell degranulation on sensitivity to heat, Inflamm. Res. 53 (2004), 309-315.
39. C. Dianzani, M. Collino, G. Lombardi, G. Garbarino and R. Fantozzi, Substance P increases neutrophil adhesion to human umbilical vein endothelial cells, Br. J. Pharmacol. 139 (2003), 1103-1110.
40. A. Ohlen, A. Thureson-Klein, L. Lindbom, M.G. Persson and P. Hedqvist, Substance P activates leukocytes and platelets in rabbit microvessels, Blood Vessels 26 (1989), 84-94.
41. R. Dix, T. Orth, J. Allen, J.G. Wood and N.C. Gonzalez, Activation of mast cells by systemic hypoxia, but not by local hypoxia, mediates increased leucocyte-endothelial adherence in cremaster venules, J. Appl. Physiol. 95 (2003), 2495-2502.
42. M.H. Howlader and P.D. Coleridge-Smith, Relationship of plasma vascular endothelial growth factor to CEAP clinical stage and symptoms in patients with chronic venous disease, Eur. J. Vasc. Endovasc. Surg. 27 (2004), 89-93.
43. Y. Guo, L. Lindbom and P. Hedqvist, Spontaneous leukocyte rolling in rat and mouse microvessels is independent of mast cell activity, Inflamm. Res. 49 (2000), 325-329.
44. I.A. Strigo, M.C. Bushnell, M. Boivin and G.H. Duncan, Psychological analysis of visceral and cutaneous pain in human subjects, Pain 97 (2002), 235-246.
45. A. Serrie, [Pain management, a new culture], Presse Med. 33 (2004), Sp13-16.
46. K. Singbarti, S.A. Green and K. Ley, Blocking P-selectin protects from ischemia-reperfusion induced acute renal failure, FASEB J. 14 (2000), 48-54.
47. M. Renard, F. Heutte, O. Boutherin-Falson, M. Finet and M.R. Boisseau, Induced changes of leukocyte slow rolling in an in flow pharmacological model of adhesion to endothelial cells, Biorheology 40 (2003), 173-178.
48. C. Michiels, J. Remacle and N. Bouaziz, Endothelium venotropic drugs in chronic venous insufficiency: a review, Phlebology 17 (2002), 145-150.
49. D. Janssens, E. Delaive, A. Houblon, F. Eliaers, J. Remacle and C. Michiels, Effect of venotropic drugs on the respiratory activity of isolated mitochondria and in endothelial cells, Br. J. Pharmacol. 130 (2000), 1513-1524.
50. B. Friesenecker, A.G. Tsai, C. Allegra and M. Intaglietta, Oral administration of purified micronized flavonoid fraction suppresses leukocyte adhesion in ischemia-reperfusion injury: in vivo observation in the hamster skin fold, Int. J. Microcirc. 14 (1994), 50-55.
51. S.S. Shoab, J.H. Scurr and P.D. Coleridge-Smith, Increased plasma endothelial growth factor among patients with chronic venous disease, J. Vasc. Surg. 271 (1998), H2520-H2528.
52. S.S. Shoab, J.H. Scurr and P.D. Coleridge-Smith, Plasma VEGF as a marker of therapy in patients with chronic venous disease treated with oral micronised flavonoid fraction, a pilot study, Eur. J. Vasc. Endovasc. Surg. 18 (1999), 334-338.
53. S. Takase, L. Pascarella, L. Lerond, J.J. Bergan and G.W. Schmid-Schönbein, Venous hypertension, inflammation and valve remodeling, Eur. J. Vasc. Endovasc. Surg. 28 (2004), 484-493.
54. S. Takase, L. Lerond and J.J. Bergan et al., The inflammatory reaction during venous hypertension in the rat, Microcirculation 7 (2000), 41-52.
55. R.J. Korthuis and D.C. Gute, Postischemic leucocyte/endothelial cell interactions and microvascular barrier dysfunction in skeletal muscle: cellular mechanisms and effect of Daflon 500 mg, Int. J. Microcirc. Clin. Exp. 17 (suppl. 1) (1997), 11-17.
56. E. Bouskela and K.A. Donyo, Effects of oral administration of purified micronized flavonoid fraction on increased microvascular permeability induced by various agents and on ischemia/ reperfusion in the hamster cheek pouch, Angiology 48 (1997), 391-399.
57. E. Bouskela, F.Z. Cyrino and L. Lerond, Micronization enhances the protective effect of purified flavonoid fraction on postischemic microvascular injury in the hamster cheek pouch, Int. Angiol. 20 (Suppl. 1) (2001), 19.
58. T. Jean and M.C. Bodinier, Mediators involved in inflammation: effects of Daflon 500 mg on their release, Angiology 45 (1994), 554-559.
59. M. Damon, O. Flandre and F. Michel et al., Effect of chronic treatment with a purified flavonoid fraction on inflammatory granuloma in the rat. Study of prostaglandin E2 and F2 alpha and thromboxane B2 release and histological changes, Arzneimittelforschung 37 (1987), 1149-1153.
60. J. Bergan, Leukocytes and venous valve damage in chronic venous disease, Medicographia 28 (2006), 101-108.
61. P. Coleridge-Smith, C. Lok and A.A. Ramelet, Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction, Eur. J. Vasc. Endovasc. Surg. 30 (2005), 198-208.
62. R.T. Eberhardt and J.D. Raffetto, Chronic venous insufficiency, Circulation 111 (2005), 2398-2409.
63. A. Lyseng-Williamson and C.M. Perry, Micronised purified flavonoid fraction. A review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids, Drugs 63 (2003), 71-100.